Skip to main content

09-09-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: CheckMate 817 trial of nivolumab–ipilimumab

Is first-line nivolumab–ipilimumab a feasible option for certain subgroups of advanced non-small-cell lung cancer patients, such as those with poor functional status? Fabrice Barlesi takes us through the CheckMate 817 trial addressing this question (3:32).

Read more about the CheckMate 817 trial here

Related topics